Cantargia logo, biotechnology company developing antibody-based treatments for cancer and autoimmune diseases
About
About Cantargia Strategy Business development Board of Directors Management Team Careers
Research & development
Scientific background Our therapeutic areas Our clinical trials Our patents Publications and scientific presentations
Pipeline
Investor relations
Share information Analyst coverage Financial reports Financial calendar Event calendar Corporate governance General meetings Rights Issue
ESG
ESG Corporate Governance Whistleblowing
Newsroom
News and press releases Analyses and presentations Subscribe Media contact Media library
Contact Change language to Swedish 

Press releases

* (R) = Regulatory press releases

Nov 9, 2026

Cantargia Announces IL-17 as Second Target for Bispecific CAN14 Antibody

Nov 5, 2026

Cantargia to host Q3 2026 Interim Results Conference Call

Nov 4, 2026

(R) Cantargia Presents Promising Early Results with Nadunolimab in MDS and AML Ahead of ASH 2026

Oct 29, 2026

(R) Cantargia presents Nomination Committee ahead of 2027 AGM

Oct 27, 2026

Cantargia to Present at the Stifel 2026 Healthcare Conference

Oct 26, 2026

(R) Cantargia appoints Dr. Monic Stuart as Chief Medical Officer

Sep 30, 2026

Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC

Aug 28, 2026

Cantargia to Participate in Upcoming Investor Conferences

Aug 19, 2026

(R) Cantargia publishes Half-Year Report 2026

Aug 4, 2026

Cantargia to host Q2 2026 Interim Results Conference Call

Older press releases >>

In media

Interview with Thoas Fioretos, co-founder and David Liberg, CSO, on nadunolimab in MDS&AML

BioStock

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

Cantargia logo

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB